Healthcare

Johnson & Johnson (NYSE: JNJ) ended fiscal 2025 on a high note, reporting higher revenues and strong earnings growth for…

Zenas BioPharma, Inc. (ZBIO) reported Q4 2025 GAAP loss of $1.39 per share, a wider loss than the -$1.19 estimate…

Alto Neuroscience reports Q4 loss of $2.19/share, 434% wider than the $0.41 estimate, with zero revenue as clinical-stage biotech continues…

HealthEquity reports Q4 fiscal 2026 on March 17 with Wall Street expecting 30% EPS growth, but recent price target cuts…

**Minerva Neurosciences Reports Q4 2025 Results**

**Verrica Pharmaceuticals Reports Q4 2025 Results**

Rapport Therapeutics Inc (RAPP) posted a Q4 2025 gaap loss of $0.72 per share, wider than the -$0.67 expected loss…

**Nuwellis Inc Reports Q4 2025 Results**

**Tenax Therapeutics Narrows Q4 Loss, Beats Expectations**

Ultralife Corp (ULBI) reported Q4 2025 gaap earnings of $0.01 per share. No consensus estimate was available for comparison. Top-line…